
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (... Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 0.0981354268891 | 5.095 | 6.54 | 5 | 101769 | 5.69374797 | CS |
4 | 0.92 | 22.009569378 | 4.18 | 6.54 | 3.6008 | 81627 | 4.66865681 | CS |
12 | -4.8 | -48.4848484848 | 9.9 | 11.55 | 3.37 | 81906 | 6.30528808 | CS |
26 | -4.86 | -48.7951807229 | 9.96 | 17.31 | 3.37 | 105365 | 10.36916931 | CS |
52 | -10.9 | -68.125 | 16 | 17.31 | 3.37 | 108487 | 10.66350505 | CS |
156 | -10.9 | -68.125 | 16 | 17.31 | 3.37 | 108487 | 10.66350505 | CS |
260 | -10.9 | -68.125 | 16 | 17.31 | 3.37 | 108487 | 10.66350505 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions